1. Acetylcholine (ACh) is synthesized in cholinergic nerve terminals from two precursors. Which of the following correctly identifies these precursors, the enzyme responsible for synthesis, and the rate-limiting factor governing the rate of ACh production?

• A) ACh is synthesized from glutamate and acetyl-CoA by the enzyme choline acetyltransferase (ChAT); the rate-limiting step is the availability of acetyl-CoA, which is produced in the mitochondria and must be transported into the cytoplasm; high-frequency firing depletes acetyl-CoA faster than it can be replenished, explaining why cholinergic transmission fatigues at very high stimulation frequencies
• B) ACh is synthesized from serine and acetyl-CoA by the enzyme acetylcholinesterase (AChE); serine is actively transported into the nerve terminal by a high-affinity serine transporter; the rate-limiting step is serine availability; acetylcholinesterase serves a dual role as both the synthetic enzyme and the degradative enzyme depending on substrate concentration
• C) ACh is synthesized from choline and acetyl-CoA by the enzyme choline acetyltransferase (ChAT); choline is transported into the nerve terminal by a high-affinity choline transporter (ChT1 — also called the hemicholinium-sensitive choline transporter); choline availability is the rate-limiting factor because choline cannot be synthesized de novo in sufficient quantities by neurons and must be retrieved from the synapse after ACh hydrolysis or supplied from plasma; hemicholinium-3 blocks ChT1, depleting choline and progressively reducing ACh synthesis with repeated stimulation
• D) ACh is synthesized from choline and acetyl-CoA by choline acetyltransferase; the rate-limiting step is ChAT enzyme activity, which is regulated by end-product inhibition — as ACh accumulates in the cytoplasm it allosterically inhibits ChAT; ACh synthesis therefore automatically ceases when cytoplasmic ACh reaches a threshold concentration, preventing vesicular overloading
• E) ACh is synthesized from acetate and choline by acetyl-CoA synthetase in the synaptic cleft; the synthesized ACh is immediately taken up into synaptic vesicles; the rate-limiting step is acetate availability from the extracellular fluid; hemicholinium-3 blocks acetate uptake, explaining its inhibitory effect on cholinergic transmission

2. After synthesis in the cytoplasm, ACh must be packaged into synaptic vesicles for storage and release. Which of the following correctly describes the vesicular storage mechanism and identifies the drug that specifically disrupts it?

• A) ACh is packaged into synaptic vesicles by a vesicular ACh transporter (VAChT — a proton-antiporter that exchanges cytoplasmic ACh for intravesicular protons); VAChT is inhibited by atropine, which blocks vesicular ACh loading and progressively depletes vesicular ACh stores with repeated nerve stimulation; this is the primary mechanism of atropine's anticholinergic effect
• B) ACh is stored in synaptic vesicles by passive diffusion — ACh is positively charged at physiological pH and is electrostatically attracted to the negatively charged interior of synaptic vesicles; no transporter is required; vesamicol has no effect on this process because passive storage cannot be pharmacologically blocked
• C) ACh is packaged into synaptic vesicles by the vesicular ACh transporter (VAChT), which uses the energy of the proton electrochemical gradient across the vesicle membrane (maintained by a vacuolar-type H+-ATPase) to drive ACh into the vesicle in exchange for protons; vesamicol specifically blocks VAChT, preventing ACh loading into vesicles; with repeated stimulation, vesamicol progressively depletes vesicular ACh stores, reducing quantal release without affecting ACh synthesis
• D) ACh is packaged into synaptic vesicles by the same transporter that packages norepinephrine — VMAT2 (vesicular monoamine transporter 2); this shared transport mechanism explains why reserpine, which blocks VMAT2, also depletes vesicular ACh in addition to depleting monoamine stores
• E) ACh is stored in synaptic vesicles without a transporter — it spontaneously condenses into vesicles along with ATP and proteoglycans; the condensation is driven by interactions between ACh and the proteoglycan matrix; botulinum toxin disrupts this condensation process, explaining its inhibitory effect on cholinergic transmission

3. Acetylcholine is released from synaptic vesicles by calcium-dependent exocytosis. Botulinum toxin (BoNT) and black widow spider venom (alpha-latrotoxin) both affect ACh release but through opposite mechanisms. Which of the following correctly describes both mechanisms and their clinical or pharmacological consequences?

• A) Botulinum toxin causes massive uncontrolled ACh release by inserting into the presynaptic membrane and forming non-selective cation channels; the resulting ACh flood produces sustained depolarization at the neuromuscular junction causing spastic paralysis; black widow spider venom blocks calcium entry into the nerve terminal by blocking voltage-gated calcium channels, reducing ACh release and causing flaccid paralysis
• B) Botulinum toxin inhibits ACh release by cleaving SNARE proteins (SNAP-25, syntaxin, synaptobrevin/VAMP) that are essential for synaptic vesicle docking and fusion with the presynaptic membrane; without functional SNARE proteins, calcium-triggered vesicle fusion cannot occur and ACh exocytosis is blocked, producing flaccid paralysis at the neuromuscular junction and autonomic cholinergic synapses; black widow spider venom (alpha-latrotoxin) causes massive uncontrolled ACh release by inserting into the presynaptic membrane and forming cation channels or by directly activating the vesicle fusion machinery, depleting ACh stores and initially causing muscle cramps and autonomic stimulation followed by weakness
• C) Botulinum toxin and black widow spider venom both inhibit ACh release but through different mechanisms — botulinum toxin blocks voltage-gated calcium channels at the nerve terminal while black widow spider venom cleaves synaptotagmin, the calcium sensor that triggers vesicle fusion; both produce flaccid paralysis but with different time courses reflecting different rates of calcium channel blockade versus synaptotagmin cleavage
• D) Botulinum toxin selectively blocks muscarinic receptors at autonomic ganglia without affecting neuromuscular junction nicotinic receptors; its clinical effects are therefore limited to autonomic dysfunction (dry mouth, urinary retention, constipation) without motor weakness; black widow spider venom selectively targets nicotinic receptors at the NMJ causing depolarizing blockade and muscle fasciculations
• E) Botulinum toxin and black widow spider venom both affect ACh release by competing with calcium for binding to synaptotagmin — the vesicular calcium sensor that initiates exocytosis; botulinum toxin is a calcium antagonist at synaptotagmin producing incomplete blockade; black widow spider venom is a calcium agonist at synaptotagmin producing supranormal release; the ratio of toxin to calcium determines whether inhibition or stimulation predominates

4. After ACh is released into the synapse, it is rapidly inactivated by acetylcholinesterase (AChE). Which of the following correctly describes the mechanism of ACh inactivation and identifies the fate of the products of hydrolysis?

• A) AChE inactivates ACh by oxidizing it to an inactive aldehyde metabolite in the synaptic cleft; the aldehyde product is then taken up by the postsynaptic cell and further metabolized by MAO; choline is not produced by this reaction and must be synthesized de novo by the nerve terminal for each cycle of ACh synthesis
• B) AChE inactivates ACh by transferring the acetyl group to coenzyme A in the synaptic cleft, regenerating free CoA and releasing choline; the acetyl-CoA produced is taken up by mitochondria in the nerve terminal for ATP production; choline diffuses away from the synapse and is lost, requiring continuous dietary supply for sustained cholinergic transmission
• C) AChE cleaves ACh by methylating the ester bond using S-adenosylmethionine as the methyl donor; the methylated choline product (betaine) is taken up by the nerve terminal and demethylated back to choline for reuse; acetate is released into the extracellular fluid; this COMT-like methylation reaction is the primary reason AChE inhibitors are structurally similar to COMT inhibitors
• D) AChE hydrolyzes ACh at the ester bond, producing choline and acetate; the reaction is extraordinarily fast — one AChE molecule can hydrolyze approximately 25,000 ACh molecules per second; choline is recovered by ChT1 (the high-affinity choline transporter) on the presynaptic membrane for resynthesis of ACh; acetate diffuses into the extracellular space; because choline recovery is essential for sustained ACh synthesis, blockade of ChT1 by hemicholinium-3 progressively depletes ACh stores
• E) AChE inactivates ACh by sequestering it into the postsynaptic cell via receptor-mediated endocytosis — when ACh binds to its receptor, the ACh-receptor complex is internalized and ACh is degraded intracellularly by lysosomal hydrolases; AChE in the synaptic cleft serves only a minor role and is not rate-limiting for ACh clearance

5. Two structurally distinct forms of acetylcholinesterase (AChE) exist at different anatomical locations and have different pharmacological significance. Which of the following correctly describes the distribution and pharmacological relevance of synaptic versus non-synaptic AChE?

• A) Synaptic AChE (anchored at the NMJ and cholinergic synapses by collagenic tail subunits attached to the basement membrane) is responsible for rapid ACh hydrolysis terminating neuromuscular and autonomic cholinergic transmission; non-synaptic AChE (the globular G4 form circulating in plasma and on red blood cell membranes — also called pseudocholinesterase or butyrylcholinesterase) hydrolyzes succinylcholine, mivacurium, and ester-type local anesthetics; these are pharmacologically distinct — true AChE (synaptic) is the therapeutic target of AChE inhibitors used for myasthenia gravis and Alzheimer's disease; butyrylcholinesterase (plasma) is not a therapeutic target but its inherited deficiency causes prolonged succinylcholine-induced paralysis
• B) Synaptic AChE and non-synaptic AChE are identical enzymes with identical substrate specificity; the only difference is their anatomical location; inhibiting synaptic AChE and plasma AChE with the same drug dose produces identical pharmacological effects at the NMJ and at plasma
• C) Non-synaptic AChE (on red blood cell membranes) is the therapeutic target of all AChE inhibitors used clinically — drugs like neostigmine and physostigmine inhibit exclusively the red blood cell form and have no effect on synaptic AChE at the NMJ or autonomic ganglia; synaptic AChE is a distinct isoenzyme that is not inhibited by any currently available drug
• D) Synaptic AChE is the primary enzyme responsible for succinylcholine hydrolysis — succinylcholine is a structural analog of two ACh molecules linked end-to-end; synaptic AChE at the NMJ rapidly hydrolyzes succinylcholine, explaining its ultra-short duration of action; patients with synaptic AChE deficiency have prolonged succinylcholine-induced paralysis
• E) There is only one form of AChE in the body — the synaptic form; plasma contains no acetylcholinesterase activity; the prolonged paralysis seen in some patients after succinylcholine results from NMJ receptor polymorphisms that cause the nicotinic receptor to remain open for an abnormally long time, independent of any enzymatic variation

6. ACh acts on two major receptor families — muscarinic and nicotinic — that differ fundamentally in structure, signal transduction, and tissue distribution. Which of the following correctly distinguishes these two receptor families at the molecular level?

• A) Muscarinic and nicotinic receptors are both ligand-gated ion channels that open in response to ACh binding; muscarinic receptors are selective for sodium while nicotinic receptors are selective for calcium; the distinction explains why muscarinic activation produces slow depolarization while nicotinic activation produces rapid depolarization
• B) Muscarinic receptors are ligand-gated ion channels (ionotropic receptors) that mediate rapid millisecond-timescale responses; nicotinic receptors are G protein-coupled receptors (metabotropic receptors) that mediate slower second-messenger-mediated responses; this distinction explains why ganglionic transmission (mediated by muscarinic receptors) is slower than neuromuscular transmission (mediated by nicotinic receptors)
• C) Muscarinic receptors (M1–M5) are G protein-coupled receptors (GPCRs) — seven-transmembrane domain proteins that couple to Gq (M1, M3, M5) or Gi (M2, M4) to activate or inhibit intracellular second messenger cascades; nicotinic receptors (NM [neuromuscular] and NN [neuronal] subtypes) are ligand-gated ion channels (ionotropic receptors) — pentameric structures that, upon ACh binding, open a non-selective cation channel producing rapid membrane depolarization; the fundamental difference is ionotropic (fast, direct) versus metabotropic (slower, second messenger-mediated) signal transduction
• D) Muscarinic receptors (M1–M5) are G protein-coupled receptors while nicotinic receptors are ligand-gated ion channels; however, in practice both receptor types produce responses on the same millisecond timescale because GPCR signaling at muscarinic receptors is unusually fast due to direct G protein gating of ion channels without second messenger involvement; the distinction is therefore pharmacological rather than kinetic
• E) Muscarinic and nicotinic receptors are identical in structure — both are pentameric ligand-gated ion channels; they differ only in their ligand binding site geometry, which determines their pharmacological selectivity; muscarine and nicotine compete for the same binding site but produce different downstream effects through allosteric receptor conformational differences

7. Muscarinic receptor subtypes M1 through M5 are distributed across different tissues and couple to different G proteins. Which of the following correctly maps the clinically important muscarinic subtypes to their tissue locations and G protein coupling?

• A) M1 receptors are expressed in cardiac SA node tissue and couple to Gs, increasing heart rate; M2 receptors are expressed in gastric parietal cells and couple to Gq, stimulating acid secretion; M3 receptors are expressed in CNS neurons and couple to Gi, producing neuronal inhibition; M4 and M5 receptors are expressed exclusively in smooth muscle
• B) All five muscarinic subtypes (M1–M5) couple exclusively to Gq; the different physiological responses seen in different tissues reflect differences in the downstream effectors expressed in each cell type rather than differences in G protein coupling; M1 in the CNS, M2 in the heart, and M3 in smooth muscle all activate the same PLC/IP3/calcium cascade
• C) M1 receptors (CNS neurons, gastric parietal cells, autonomic ganglia) couple to Gq — activating PLC/IP3/calcium, mediating cognitive function and gastric acid secretion; M2 receptors (cardiac SA and AV nodes, presynaptic autoreceptors) couple to Gi — inhibiting adenylyl cyclase and activating GIRK channels, slowing heart rate and reducing AV conduction; M3 receptors (smooth muscle, exocrine glands, endothelium) couple to Gq — activating PLC/IP3/calcium, mediating bronchoconstriction, increased GI motility, glandular secretion, and endothelial NO synthesis producing vasodilation
• D) M1 receptors couple to Gi throughout the body, mediating all inhibitory muscarinic effects; M2 receptors couple to Gq, mediating all excitatory muscarinic effects; M3 receptors couple to Gs, mediating smooth muscle relaxation; the numbering reflects the order in which the receptors were cloned rather than any functional distinction
• E) M2 and M3 receptors are the only clinically significant muscarinic subtypes; M1, M4, and M5 are expressed only in non-human mammalian species and have no role in human pharmacology; M2 is responsible for all inhibitory muscarinic effects and M3 is responsible for all excitatory muscarinic effects, with G protein coupling being identical for both (Gq)

8. Nicotinic receptors at the neuromuscular junction (NM subtype) differ structurally and pharmacologically from nicotinic receptors at autonomic ganglia (NN subtype). Which of the following correctly identifies these structural and pharmacological differences and explains their clinical significance?

• A) NM and NN nicotinic receptors are structurally identical pentamers composed of two alpha, one beta, one gamma, and one delta subunit; they differ only in their anatomical location; because they are structurally identical, drugs that block NM receptors at the NMJ always block NN receptors at autonomic ganglia with equal potency — no selectivity between these two sites is pharmacologically achievable
• B) NM receptors at the NMJ are pentamers containing two alpha-1 subunits plus beta-1, gamma (or epsilon in adult muscle), and delta subunits; NN receptors at autonomic ganglia are pentamers containing alpha-3 and beta-4 subunits (with variable alpha-5 and other subunits); this subunit composition difference allows pharmacological selectivity — tubocurarine (and modern neuromuscular blockers like rocuronium and vecuronium) selectively block NM receptors at the NMJ with minimal ganglionic blockade at therapeutic doses; ganglionic blockers (hexamethonium, mecamylamine) selectively block NN receptors at autonomic ganglia
• C) NM receptors at the NMJ are ligand-gated ion channels while NN receptors at autonomic ganglia are G protein-coupled receptors; this fundamental structural difference explains why neuromuscular blockers cannot be used as ganglionic blockers — they act on different receptor families; all ganglionic blockers work through GPCR-mediated second messenger pathways
• D) NN receptors at autonomic ganglia are larger pentamers (7 subunits) than NM receptors at the NMJ (5 subunits); the additional two subunits in NN receptors form a separate regulatory domain that confers sensitivity to hexamethonium; NM receptors lack this regulatory domain and are therefore insensitive to hexamethonium at any dose
• E) NM and NN nicotinic receptors differ only in their membrane localization — NM receptors are located exclusively in the extrajunctional membrane (outside the end-plate zone) while NN receptors are located exclusively within the junctional cleft; this topographical difference determines which drugs can access each subtype, not their intrinsic pharmacological properties

9. A student encounters the term "autonomic ganglia" and asks: "ACh is released at both the parasympathetic ganglia and the parasympathetic end-organ — but it activates nicotinic receptors at the ganglion and muscarinic receptors at the end-organ. How does the same neurotransmitter produce different effects at different anatomical locations?" Which of the following best answers this question?

• A) The same ACh molecule cannot activate both nicotinic and muscarinic receptors — at autonomic ganglia, ACh is chemically modified by ganglionic enzymes to a form that specifically activates nicotinic receptors; at the end-organ, a different chemical modification produces the muscarinic-active form; the chemical transformation is location-specific and explains the receptor selectivity
• B) The receptor type expressed at each anatomical location — not the chemical identity of the neurotransmitter — determines the pharmacological response; autonomic ganglionic neurons express nicotinic (NN) receptors because fast ionotropic transmission is needed for reliable signal relay across the ganglion; parasympathetic target tissues express muscarinic receptors because slower GPCR-mediated responses are appropriate for the graded, sustained regulatory functions of parasympathetic end-organ activation; the same ACh molecule activates whichever receptor type is expressed at its release site — this is the principle of receptor-dependent pharmacology that applies across all neurotransmitter systems
• C) ACh activates nicotinic receptors at autonomic ganglia because ganglionic ACh is released from vesicles with a different molecular weight than end-organ ACh — large-vesicle ACh preferentially binds nicotinic receptors while small-vesicle ACh preferentially binds muscarinic receptors; the vesicle size difference at each anatomical location determines receptor selectivity
• D) The distinction between ganglionic and end-organ ACh receptor activation is pharmacological rather than physiological — in vivo, ACh activates both nicotinic and muscarinic receptors simultaneously at every cholinergic synapse; the apparent selectivity is an artifact of in vitro studies using isolated tissue preparations; in intact organisms, blocking either receptor type at any cholinergic synapse produces identical functional effects
• E) ACh at autonomic ganglia is co-released with substance P, which allosterically shifts nicotinic receptor conformation to the high-affinity state; at parasympathetic end-organs, ACh is co-released with VIP (vasoactive intestinal peptide), which allosterically shifts muscarinic receptor conformation to the high-affinity state; without these co-transmitters, ACh would activate both receptor types equally at both locations

10. A 42-year-old man eats food contaminated with Clostridium botulinum toxin at a catered event. Over the following 12–36 hours he develops descending flaccid paralysis, dysarthria, diplopia, and dry mouth. His pupils are dilated. Which of the following best explains this clinical presentation using cholinergic synapse pharmacology?

• A) The clinical presentation reflects systemic muscarinic receptor overstimulation — botulinum toxin is a muscarinic receptor agonist that activates all five muscarinic subtypes simultaneously; the resulting parasympathetic overdrive produces the descending weakness through CNS muscarinic activation and the autonomic symptoms through peripheral M2 and M3 activation; the flaccid paralysis results from excess M3 activation in skeletal muscle
• B) The clinical presentation reflects excess ACh at nicotinic receptors only — botulinum toxin inhibits AChE, allowing ACh to accumulate selectively at nicotinic synapses; the resulting persistent nicotinic receptor depolarization produces depolarizing blockade and flaccid paralysis; muscarinic symptoms are absent because AChE is not present at muscarinic synapses
• C) The clinical presentation reflects blockade of ACh release at all cholinergic terminals — botulinum toxin cleaves SNARE proteins preventing ACh exocytosis; without ACh release, neuromuscular junction nicotinic receptors are not activated (producing flaccid paralysis), autonomic ganglionic nicotinic receptors are not activated (impairing autonomic reflexes), and parasympathetic end-organ muscarinic receptors receive no ACh (producing the anti-muscarinic symptoms: dry mouth from reduced salivary gland secretion, dilated pupils from loss of iris sphincter M3 stimulation, and failure of accommodation); the presentation spans all three cholinergic synapse types simultaneously
• D) The clinical presentation reflects selective blockade of NM nicotinic receptors at the NMJ by botulinum toxin binding postsynaptically; autonomic symptoms are caused by concurrent botulinum toxin binding to alpha-1 adrenergic receptors, producing sympathetic-like effects (dilated pupils, dry mouth) through adrenergic receptor blockade paradoxically releasing sympathetic tone
• E) The clinical presentation reflects botulinum toxin's selective inhibition of ChAT — the synthetic enzyme for ACh; without ChAT activity, ACh synthesis ceases; stores are progressively depleted with each nerve firing; the descending pattern reflects the order in which cholinergic neurons exhaust their pre-existing ACh stores, with cranial nerve-innervated muscles depleting their stores first due to higher baseline firing rates

11. A pharmacologist administers a drug to an experimental animal and observes the following effects: bradycardia, increased salivation, bronchoconstriction, increased GI motility, and miosis (pupillary constriction). A second drug, when administered before the first, completely blocks all of these effects. Which of the following correctly identifies the receptor subtype mediated by the first drug and the mechanism of the second drug?

• A) The first drug activates nicotinic (NN) receptors at autonomic ganglia — stimulating all postganglionic autonomic neurons simultaneously produces the mixed sympathetic and parasympathetic effects observed; bradycardia reflects cardiac parasympathetic dominance in ganglionic stimulation; the second drug is a ganglionic blocker (hexamethonium) that blocks NN receptors, preventing all ganglionic transmission
• B) The first drug activates nicotinic (NM) receptors at the neuromuscular junction — sustained NMJ activation produces the autonomic-appearing effects through motor neuron feedback loops to the brainstem; the second drug is a non-depolarizing neuromuscular blocker (rocuronium) that blocks NM receptors
• C) The first drug activates muscarinic receptors — the observed effects (bradycardia from M2 activation in SA node, increased salivation from M3 activation in salivary glands, bronchoconstriction from M3 activation in bronchial smooth muscle, increased GI motility from M1/M3 activation in GI tract, miosis from M3 activation in iris sphincter muscle) are the classic signs of parasympathetic/muscarinic stimulation; the second drug is a muscarinic receptor antagonist (atropine) that competitively blocks all muscarinic receptor subtypes, reversing all the observed effects
• D) The first drug activates both muscarinic and nicotinic receptors simultaneously — the observed effects represent mixed agonism at both receptor families; the second drug is selective for nicotinic receptors and blocks only the NMJ effects; the bradycardia, salivation, and other autonomic effects persist because they are muscarinic-mediated and not blocked by the second drug
• E) The first drug inhibits acetylcholinesterase, causing ACh accumulation at all cholinergic synapses and producing a mixed muscarinic and nicotinic stimulation syndrome; the second drug reverses this by reactivating AChE through covalent bond cleavage; this reactivation mechanism is the basis of pralidoxime's use in organophosphate poisoning

12. At the conclusion of Module 1, a student reflects: "The cholinergic system uses one neurotransmitter — ACh — to control an enormous range of physiological functions, from the heartbeat to the pupil to skeletal muscle to cognition. What single pharmacological principle makes this possible without creating pharmacological chaos where stimulating one function inevitably stimulates all the others?" Which of the following best captures this principle?

• A) Pharmacological specificity is achieved through chemical modification of ACh at each synapse — pre-release enzymatic processing converts ACh into distinct molecular variants (N-methyl-ACh at cardiac synapses, deacyl-ACh at smooth muscle synapses, intact ACh at the NMJ); each variant activates only its target receptor type; drugs that mimic or block ACh must be chemically matched to the specific variant at their target synapse
• B) Pharmacological specificity in the cholinergic system is achieved through receptor subtype diversity combined with tissue-specific receptor expression — ACh itself is pharmacologically non-selective (it can activate all cholinergic receptor types), but each tissue expresses only the receptor subtype appropriate to its function; M2 in the SA node produces bradycardia; M3 in bronchial smooth muscle produces bronchoconstriction; NM at the NMJ produces muscle contraction; NN at autonomic ganglia enables ganglionic transmission; a drug that selectively targets one receptor subtype can modulate one physiological function without necessarily affecting all others — and understanding receptor subtype distribution allows prediction of both therapeutic effect and adverse effect profile for every cholinergic drug
• C) Pharmacological specificity is achieved through compartmentalization of ACh release — each physiological function is controlled by a dedicated ACh isoform secreted only within anatomically sealed synaptic compartments that prevent ACh from reaching any receptor other than its designated target; AChE is expressed only within these sealed compartments, ensuring that systemically administered drugs cannot access individual synaptic compartments and must be administered locally
• D) Pharmacological specificity does not exist in the cholinergic system — stimulating any cholinergic receptor always activates all cholinergic functions simultaneously; clinical cholinergic drugs produce predictably broad effects across all ACh-mediated functions; specificity of clinical effect is achieved not through receptor selectivity but through dose titration to keep effects below the threshold for unwanted responses
• E) Pharmacological specificity in the cholinergic system is achieved because ACh is only released at one type of cholinergic synapse at a time — the nervous system coordinates ACh release so that NMJ, ganglionic, and parasympathetic end-organ synapses never fire simultaneously; the temporal separation of ACh release at different synapse types prevents receptor cross-activation